The ATTACK consortium invites you to a three day symposium to discuss recent developments in engineered T cell therapy for cancer and related areas of cancer immunotherapy. The conference will cover basic and translational research through to clinical trials in this exciting field.

Confirmed Speakers will include:

Hinrich Abken - University of Cologne, Germany  
Thomas Blankenstein - MDC, Germany  
Chiara Bonini, - San Raffaele Scientific Institute, Italy  
Claudio Bordignon - Molmed, Italy  
Richard Childs - NIH, USA  
Philip Darcy - Peter McCallum Cancer Institute, Australia  
Reno Debets - Erasmus MC Daniel, The Netherlands  
Mark Dudley - NCI, USA  
Zelig Eshhar - Weizmann Institute of Science, Israel  
David Gilham - University of Manchester, UK  
Phil Greenberg - University of Washington, Seattle  
Robert Hawkins - University of Manchester - UK  
(ATTACK Co-ordinator)  
Mike Jensen - City of Hope National Medical Centre, USA  
Carl June - Abramson Family Cancer Research Institute, USA  
Michael Kershaw - Peter McCallum Cancer Institute, Australia  
Hans Kolb - University of Munich, Germany  
Claire Lewis - University of Sheffield, UK  
Andreas Mackensen - Regensburg University, Germany  
Alberto Mantovani - Humanitas, Italy  
Anna Mondino - San Raffaele Scientific Institute, Italy  
Michel Morre - Cytheris, France  
Pamela Ohashi - Ontario Cancer Institute, Canada  
Nick Restifo - NCI, USA  
Cliona Rooney - Baylor College of Medicine, USA  
Michel Sadelain - MSKCC, USA  
Ton Schumacher - Netherlands Cancer Institute, Netherlands  
Andrew Sewell - University of Cardiff, UK  
Charlie Surh - Scripps Research Institute, USA  
Naomi Taylor - CNRS, France  
Wolfgang Uckert - MDC, Germany